Solid Tumor
Conditions
Keywords
Solid tumor, Breast cancer, Head & Neck cancer
Brief summary
A phase I, open-label, dose-finding study to assess the safety, tolerability and pharmacokinetics of ISU104, a human monoclonal antibody targeting erbB3 in patients with advanced solid tumors.
Detailed description
\[Part 1 Dose-escalation\] This study ams to evaluate the safety, tolerability, and pharmacokinetics of ISU104 in patients with advanced solid tumors. Primary objective To determine recommended Phase II dose (RP2D) of ISU104 based on the results of its safety and tolerability in patients with advanced solid tumors. Secondary objectives 1. To evaluate pharmacokinetics (PK) of ISU104 in patients with advanced solid tumors. 2. To evaluate efficacy of ISU104 in patients with advanced solid tumors. Exploratory purpose To identify the expression of explorable multiple tumor biomarkers and to analyze the relationship between biomarkers and antitumor activity of ISU104. \[Part 2 dose-expansion\] The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ISU104 in patients with recurrent/metastatic HNSCC (except for nasopharyngeal cancer), when administered intravenously ISU104 alone or ISU104 in combination with cetuximab. Primary objective To determine RP2D of ISU104 based on results of its safety and tolerability in patients with recurrent/metastatic HNSCC (except for nasopharyngeal cancer), when administered intravenously ISU104 only or ISU104 in combination with cetuximab. Secondary objectives 1. To evaluate the pharmacokinetics of ISU104 in patients with recurrent/metastatic HNSCC (except for nasopharyngeal cancer), when administered intravenously ISU104 only or ISU104 in combination with cetuximab. 2. To evaluate the efficacy of ISU104 in patients with recurrent/metastatic HNSCC (except for nasopharyngeal cancer), when administered intravenously ISU104 only or ISU104 in combination with cetuximab. Exploratory purpose To explore a variety of detectable tumor biomarkers and evaluate the relationship between these biomarkers and antitumor activity of ISU104.
Interventions
BIOLOGICALISU104
Intravenous Infusion for 1 hour.
DRUGCetuximab
Intravenous Infusion for 1 hour (2 hours at initial dose)
Sponsors
ISU Abxis Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
A. Part 1: Dose escalation * Total 15 subjects: 3 subjects in each dose level * 1mg/kg/day, 3mg/kg/day, 5mg/kg/day, 10mg/kg/day, 20mg/kg/day B. Part 2: Dose expansion * Group 1 (Mono-therapy: 20 mg/kg/day, Q3W): 6 subjects * Group 2 (Combination therapy with cetuximab 400 mg/m2 followed by 250 mg/m2, Q1W): 12 subjects
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Common 1. Male or Female with ≥ 19 years of age 2. Histologically or Cytologically confirmed a diagnosis of an advanced solid tumor that was refractory to standard treatment or for which no standard therapy existed, or patients declined any treatment options 3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 4. Life Expectancy ≥ 12 weeks 5. Adequate Hematological, Renal and Hepatic function 6. According to Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1, the patient had at least one measurable lesion
Exclusion criteria
1. Severe hypersensitivity or a history of any hypersensitivity to the similar drug class of IP 2. Patients underwent the major surgery or procedure, or had the medical history (as blow): * Major surgery requiring systemic anesthesia or respiratory assist device within 4 weeks prior to baseline \[2 weeks in case of video-assisted thoracoscopic surgery (VATS) or open-and-closed (ONC) surgery)\] * Severe cardiovascular disease within 24 weeks prior to baseline * Severe cerebrovascular disease within 24 weeks prior to baseline * Pulmonary thromboembolism, deep vein thrombosis (DVT) or other clinically and significantly severe lung disease within 24 weeks prior to baseline 3. Patients had the following concurrent diseases at baseline: * Hematologic malignancies including lymphoma * Clinically significant symptom or uncontrolled central nervous system (CNS) or brain metastases * Pleural effusion and ascites drainage * Uncontrolled hypertension (SBP/DBP \> 160/100 mmHg) * Active hepatitis B or C virus * Human immunodeficiency virus (HIV) that is positive * Thromboembolic disease or bleeding diatheses * Interstitial lung disease (ILD) 4. Left ventricular ejection fraction (LVEF) value, when measured by echocardiogram, multiple gated acquisition (MUGA) scan or a standard procedure in the institution within 4 weeks prior to the study entry 5. Patients with the following medication history: * anti-ErbB3 targeted therapies * small-molecule tyrosine kinase inhibitors within 2 weeks prior to baseline * any anti-cancer therapy, including chemotherapy, radiotherapy, biologic therapy, retinoid therapy, or therapeutic/palliative radiotherapy for the treatment of advanced solid tumors within 4 weeks prior to baseline * Granulocyte-Colony Stimulating Factor (G-CSF), packed red cell or platelet transfusion within 2 weeks prior to the first injection of IP to correct the abnormal values of absolute neutrophil count (ANC) or platelet count 6. Pregnant woman, breastfeeding woman, or women of childbearing age and men with partners of childbearing age, unless they are willing to follow abstinence or use effective forms of contraception\* from the study entry until at least 16 weeks after the EOT visit 7. Subjects receiving any other investigational products or medical devices within 4 weeks prior to screening 8. Principal investigator's opinion \[Part 1 Dose-escalation cohort\] 1. Patients with severe hypersensitivity or history of hypersensitivity to the similar drug class of the investigational product. 2. Patients receiving anti-cancer therapy, including chemotherapy, radiotherapy, biologic therapy, retinoid therapy, or therapeutic/palliative radiotherapy for treatment of advanced solid tumors within four weeks prior to baseline. \[Part 2 dose-expansion cohort\] 1. Patients with history of allergy or hypersensitivity to the investigational product (ISU104 or cetuximab) or any excipients of the investigational product or its similar derivatives. 2. Patients with primary malignant neoplasm, including head and neck cancer as specified in inclusion criteria of Part 2 dose-expansion cohort. However, an exception may be allowed for the following: * For respective malignancy, treatment-naïve or disease-free patients for at least three years (however, patients undergoing radical resection on papillary thyroid carcinoma may be eligible for this clinical trial, even though three years have not passed). * Total dissection of skin basal cell carcinoma/squamous cell carcinoma or at least one year had passed since successful treatment of cervical intraepithelial neoplasia. 3. Patients receiving anti-cancer therapy, including chemotherapy, radiotherapy, biologic therapy, retinoid therapy, therapeutic/palliative radiotherapy, or hormone therapy for treatment of advanced solid tumors within four weeks prior to baseline.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine the Maximum Tolerated Dose Dependent on Reports of Dose-limiting Toxicities | From date of first dose to 4 weeks after administration. | Determination of MTD is dependent upon number of cohorts and patients required |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Determine Immunogenicity of ISU104 | through the study completion, an average of 1 year | To measure the level of Anti-Drug Antibody (ADA) and/or Neutralizing Antibody (NAb) of ISU104 |
| Determine the Peak Plasma Concentration (Cmax) of ISU104 | up to 12 weeks | To measure the Peak Plasma Concentration (Cmax) of ISU104 |
| Determine the Area Under the Curve (AUC) of ISU104 | up to 12 weeks | To measure the Area under the plasma concentration versus time curve (AUC) of ISU104 |
| Toxicity Evaluation | through the study completion, an average of 1 year | To determine the occurrence of Adverse Events (AEs) |
| Explore Disease Control Rate (DCR) of ISU104 or ISU104+Cetuximab | up to progression, an average 6 months | To determine the number of patients reporting an objective response using RECIST v 1.1 where a Partial Response (PR) is defined as \>30% decrease in tumor burden from baseline, a Complete Response (CR) is defined as complete disappearance from tumor burden from baseline, and Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for Partial Response nor sufficient increase to qualify for Partial Response (defined as \>20% decrease in tumor burden from baseline) |
| Explore Progression-Free Survival (PFS) of ISU104 or ISU104+Cetuximab | up to progression, an average 6 months | To measure the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse |
| Explore Overall Response Rate (ORR) of ISU104 or ISU104+Cetuximab | up to progression, an average 6 months | To determine the number of patients reporting an objective response using RECIST v 1.1 where a Partial Response (PR) is defined as \>30% decrease in tumor burden from baseline and a Complete Response (CR) is defined as complete disappearance from tumor burden from baseline |
Countries
South Korea
Outcome results
None listed